LPCN
Lipocine Inc.
Biotechnology
Market Cap$13M
5Y Perf.-84.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LPCN vs TLSA
Revenue, margins, valuation, and 5-year total return — side by side.
TLSA
Tiziana Life Sciences Ltd
Biotechnology
Market Cap$192M
5Y Perf.-43.0%
LPCN vs TLSA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LPCN | TLSA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $13M | $192M |
| Revenue (TTM) | $2M | $0.00 |
| Net Income (TTM) | $-11M | $-34M |
| Gross Margin | -13.4% | — |
| Operating Margin | -413.6% | — |
| Total Debt | $0.00 | $106K |
| Cash & Equiv. | $5M | $4M |
LPCN vs TLSA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LPCN
TLSA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Lipocine Inc. (LPCN) | 100 | 15.4 | -84.6% |
| Tiziana Life Scienc… (TLSA) | 100 | 57.0 | -43.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LPCN vs TLSA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TLSA leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Lipocine Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
LPCN
Lipocine Inc.
The Niche Pick
LPCN is the clearest fit if your priority is efficiency.
- -59.4% ROA vs TLSA's -303.2%, ROIC -64.7% vs -481.7%
Best for: efficiency
TLSA
Tiziana Life Sciences Ltd
The Income Pick
TLSA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.74
- EPS growth 35.3%
- -63.8% 10Y total return vs LPCN's -98.4%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TLSA | -57.8% revenue growth vs LPCN's -82.3% |
| Quality / Margins | TLSA | 7.2% margin vs LPCN's -5.7% |
| Stability / Safety | TLSA | Beta 0.74 vs LPCN's 0.86 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TLSA | -3.8% vs LPCN's -27.6% |
| Efficiency (ROA) | LPCN | -59.4% ROA vs TLSA's -303.2%, ROIC -64.7% vs -481.7% |
LPCN vs TLSA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
LPCN vs TLSA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTLSALAGGINGLPCN
LPCNLipocine Inc.
1leads
TLSATiziana Life Sciences…
3leads
6 Total Categories
CATEGORYLEADERvs LPCNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TLSA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LPCN6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
TLSA6/6
Risk & VolatilityBeta, volatility, and downside exposure
TLSA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TLSA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LPCN and TLSA operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | LPCNLipocine Inc. | TLSATiziana Life Scie… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $0 |
| EBITDAEarnings before interest/tax | -$8M | -$40M |
| Net IncomeAfter-tax profit | -$11M | -$34M |
| Free Cash FlowCash after capex | -$8M | -$14M |
| Gross MarginGross profit ÷ Revenue | -13.4% | — |
| Operating MarginEBIT ÷ Revenue | -4.1% | — |
| Net MarginNet income ÷ Revenue | -5.7% | — |
| FCF MarginFCF ÷ Revenue | -3.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +27.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -54.3% | +27.8% |
TLSA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — LPCN and TLSA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | LPCNLipocine Inc. | TLSATiziana Life Scie… |
|---|---|---|
| Market CapShares × price | $13M | $192M |
| Enterprise ValueMkt cap + debt − cash | $8M | $189M |
| Trailing P/EPrice ÷ TTM EPS | -1.41x | -6.86x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 6.58x | — |
| Price / BookPrice ÷ Book value/share | 0.94x | 20.46x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — LPCN and TLSA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
LPCN leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
LPCN delivers a -66.7% return on equity — every $100 of shareholder capital generates $-67 in annual profit, vs $-9 for TLSA. On the Piotroski fundamental quality scale (0–9), TLSA scores 2/9 vs LPCN's 0/9, reflecting mixed financial health.
| Metric | LPCNLipocine Inc. | TLSATiziana Life Scie… |
|---|---|---|
| ROE (TTM)Return on equity | -66.7% | -8.7% |
| ROA (TTM)Return on assets | -59.4% | -3.0% |
| ROICReturn on invested capital | -64.7% | -4.8% |
| ROCEReturn on capital employed | -58.5% | -3.3% |
| Piotroski ScoreFundamental quality 0–9 | 0 | 2 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$5M | -$4M |
| Cash & Equiv.Liquid assets | $5M | $4M |
| Total DebtShort + long-term debt | $0 | $106,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -2622.00x |
LPCN leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
TLSA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TLSA five years ago would be worth $6,345 today (with dividends reinvested), compared to $1,011 for LPCN. Over the past 12 months, TLSA leads with a -3.8% total return vs LPCN's -27.6%. The 3-year compound annual growth rate (CAGR) favors TLSA at 23.6% vs LPCN's -16.7% — a key indicator of consistent wealth creation.
| Metric | LPCNLipocine Inc. | TLSATiziana Life Scie… |
|---|---|---|
| YTD ReturnYear-to-date | -70.1% | -5.6% |
| 1-Year ReturnPast 12 months | -27.6% | -3.8% |
| 3-Year ReturnCumulative with dividends | -42.1% | +88.7% |
| 5-Year ReturnCumulative with dividends | -89.9% | -36.6% |
| 10-Year ReturnCumulative with dividends | -98.4% | -63.8% |
| CAGR (3Y)Annualised 3-year return | -16.7% | +23.6% |
TLSA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
TLSA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TLSA is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than LPCN's 0.86 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TLSA currently trades 58.1% from its 52-week high vs LPCN's 19.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LPCNLipocine Inc. | TLSATiziana Life Scie… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.86x | 0.74x |
| 52-Week HighHighest price in past year | $12.37 | $2.60 |
| 52-Week LowLowest price in past year | $1.81 | $1.14 |
| % of 52W HighCurrent price vs 52-week peak | +19.3% | +58.1% |
| RSI (14)Momentum oscillator 0–100 | 34.1 | 66.4 |
| Avg Volume (50D)Average daily shares traded | 463K | 149K |
TLSA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | LPCNLipocine Inc. | TLSATiziana Life Scie… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | 3 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TLSA leads in 3 of 6 categories (Income & Cash Flow, Total Returns). LPCN leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallTiziana Life Sciences Ltd (TLSA)Leads 3 of 6 categories
Loading custom metrics...
LPCN vs TLSA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is LPCN or TLSA a better buy right now?
Analysts rate Tiziana Life Sciences Ltd (TLSA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LPCN or TLSA?
Over the past 5 years, Tiziana Life Sciences Ltd (TLSA) delivered a total return of -36.
6%, compared to -89. 9% for Lipocine Inc. (LPCN). Over 10 years, the gap is even starker: TLSA returned -63. 8% versus LPCN's -98. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LPCN or TLSA?
By beta (market sensitivity over 5 years), Tiziana Life Sciences Ltd (TLSA) is the lower-risk stock at 0.
74β versus Lipocine Inc. 's 0. 86β — meaning LPCN is approximately 17% more volatile than TLSA relative to the S&P 500.
04Which has better profit margins — LPCN or TLSA?
Tiziana Life Sciences Ltd (TLSA) is the more profitable company, earning 0.
0% net margin versus -487. 1% for Lipocine Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TLSA leads at 0. 0% versus -524. 7% for LPCN. At the gross margin level — before operating expenses — TLSA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — LPCN or TLSA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is LPCN or TLSA better for a retirement portfolio?
For long-horizon retirement investors, Tiziana Life Sciences Ltd (TLSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
74)). Both have compounded well over 10 years (TLSA: -63. 8%, LPCN: -98. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between LPCN and TLSA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.